Neurocrine Biosciences NBIX Stock
Neurocrine Biosciences Price Chart
Neurocrine Biosciences NBIX Financial and Trading Overview
| Neurocrine Biosciences stock price | 161.44 USD |
| Previous Close | 158.29 USD |
| Open | 161.17 USD |
| Bid | 147.22 USD x 200 |
| Ask | 173.95 USD x 200 |
| Day's Range | 159.32 - 161.79 USD |
| 52 Week Range | 122.14 - 169.57 USD |
| Volume | 901.01K USD |
| Avg. Volume | 1.2M USD |
| Market Cap | 16.25B USD |
| Beta (5Y Monthly) | 0.396 |
| PE Ratio (TTM) | 24.82642 |
| EPS (TTM) | 6.49 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | December 29, 1995 |
| 1y Target Est | 194.38 USD |
NBIX Valuation Measures
| Enterprise Value | 15.06B USD |
| Trailing P/E | 24.82642 |
| Forward P/E | 12.750943 |
| PEG Ratio (5 yr expected) | 0.45 |
| Price/Sales (ttm) | 5.238167 |
| Price/Book (mrq) | 4.7716336 |
| Enterprise Value/Revenue | 4.855 |
| Enterprise Value/EBITDA | 18.179 |
Trading Information
Neurocrine Biosciences Stock Price History
| Beta (5Y Monthly) | 0.396 |
| 52-Week Change | 25.82% |
| S&P500 52-Week Change | 24.48% |
| 52 Week High | 169.57 USD |
| 52 Week Low | 122.14 USD |
| 50-Day Moving Average | 147.55 USD |
| 200-Day Moving Average | 141.29 USD |
NBIX Share Statistics
| Avg. Volume (3 month) | 1.2M USD |
| Avg. Daily Volume (10-Days) | 1.18M USD |
| Shares Outstanding | 100.55M |
| Float | 99.29M |
| Short Ratio | 4.28 |
| % Held by Insiders | 1.07% |
| % Held by Institutions | 103.90% |
| Shares Short | 5.53M |
| Short % of Float | 7.16% |
| Short % of Shares Outstanding | 5.50% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 21.55% |
| Operating Margin (ttm) | 22.83% |
| Gross Margin | 64.37% |
| EBITDA Margin | 26.70% |
Management Effectiveness
| Return on Assets (ttm) | 11.61% |
| Return on Equity (ttm) | 22.50% |
Income Statement
| Revenue (ttm) | 3.1B USD |
| Revenue Per Share (ttm) | 31.12 USD |
| Quarterly Revenue Growth (yoy) | 42.19% |
| Gross Profit (ttm) | 2B USD |
| EBITDA | 828.6M USD |
| Net Income Avi to Common (ttm) | 668.6M USD |
| Diluted EPS (ttm) | 6.51 |
| Quarterly Earnings Growth (yoy) | 2405.09% |
Balance Sheet
| Total Cash (mrq) | 1.32B USD |
| Total Cash Per Share (mrq) | 13.09 USD |
| Total Debt (mrq) | 463.5M USD |
| Total Debt/Equity (mrq) | 13.6 USD |
| Current Ratio (mrq) | 2.929 |
| Book Value Per Share (mrq) | 33.871 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 863.7M USD |
| Levered Free Cash Flow (ttm) | 590.55M USD |
Profile of Neurocrine Biosciences
| Country | United States |
| State | CA |
| City | San Diego |
| Address | 6027 Edgewood Bend Court |
| ZIP | 92130 |
| Phone | 858 617 7600 |
| Website | https://www.neurocrine.com |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 2000 |
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Q&A For Neurocrine Biosciences Stock
What is a current NBIX stock price?
Neurocrine Biosciences NBIX stock price today per share is 161.44 USD.
How to purchase Neurocrine Biosciences stock?
You can buy NBIX shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Neurocrine Biosciences?
The stock symbol or ticker of Neurocrine Biosciences is NBIX.
Which industry does the Neurocrine Biosciences company belong to?
The Neurocrine Biosciences industry is Drug Manufacturers - Specialty & Generic.
How many shares does Neurocrine Biosciences have in circulation?
The max supply of Neurocrine Biosciences shares is 100.55M.
What is Neurocrine Biosciences Price to Earnings Ratio (PE Ratio)?
Neurocrine Biosciences PE Ratio is 24.87519500 now.
What was Neurocrine Biosciences earnings per share over the trailing 12 months (TTM)?
Neurocrine Biosciences EPS is 6.49 USD over the trailing 12 months.
Which sector does the Neurocrine Biosciences company belong to?
The Neurocrine Biosciences sector is Healthcare.
Neurocrine Biosciences NBIX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25587.04 USD — |
-2.21
|
13.85B USD — | 25513.26 USD — | 25882.57 USD — | — - | 13.85B USD — |
|
Dow Jones U.S. Biotechnology In
DJUSBT
US
|
3033.18 USD — |
+1.08
|
100.05M USD — | 3015.75 USD — | 3040.05 USD — | — - | 100.05M USD — |
|
US Tech Biotechnology Total Retu
XNBI
US
|
6750.7 USD — |
+0.85
|
— — | 6680.28 USD — | 6803.27 USD — | — - | — — |
|
US Tech US Smart Pharmaceuticals
NQSSPH
US
|
1926.14 USD — |
+1.34
|
— — | 1902.55 USD — | 1929.69 USD — | — - | — — |
|
US Tech DM Ex Japan Large Mid Ca
NQDMXJPLMAUD
US
|
2100.38 AUD 1467.26 USD |
<0.01
|
— — | 2100.38 AUD 1467.26 USD | 2100.38 AUD 1467.26 USD | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
|
US Tech Composite Total Return
XCMP
US
|
31560.2 USD — |
-2.21
|
— — | 31469.2 USD — | 31924.72 USD — | — - | — — |
|
US Tech Global Select Market Com
NQGS
US
|
12546.99 USD — |
-2.24
|
— — | 12513.27 USD — | 12692.24 USD — | — - | — — |
|
US Tech Next Generation 100 Inde
NGX
US
|
1787.88 USD — |
-1.19
|
— — | 1779 USD — | 1802.31 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6185.56 USD — |
+0.85
|
— — | 6121.03 USD — | 6233.73 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1184.66 USD — |
+0.75
|
— — | 1174.72 USD — | 1192.68 USD — | — - | — — |
- {{ link.label }} {{link}}